Back to search

University of Birmingham

Genetic studies into rare diseases and cancer using next generation sequencing technologies

Abstract

dc:description.abstract

Rare genetic diseases (RGDs) and rare sporadic cancers are often considered as two separate groups of diseases. Nevertheless, both groups share the same burden: their rarity and the challenges in diagnosis and treatment, thus affecting the wellbeing of many patients and their families around the world. Although next generation sequencing (NGS) technologies have revolutionised the genetic landscape of RGDs and cancers, many patients with these diseases are still without a definitive molecular diagnosis. In this thesis, NGS was conducted on congenital hypothyroidism (CHT) families (an example of an RGD) and three rare bone cancers, aiming to expand the understanding of the genetic and pathogenic mechanisms of these diseases. To identify known or novel disease-causing genes, WES was conducted on four families with CHT. In one family, a homozygous candidate variant in SIX2 was identified, and subsequent functional characterisation experiments and family segregation analyses were performed. After more family members were included, the SIX2 variant did not segregate with the disease in the family and, therefore, was classified as unlikely disease causing. WES and RNA sequencing (RNA-Seq) were conducted on three rare bone tumours: undifferentiated pleomorphic sarcoma of bone (UPSb), adamantinoma and osteofibrous dysplasia (OFD)-like adamantinoma. In UPSb tumours, 31 genes were recurrently mutated, including TP53 in 4/14 samples (29%), and chromatin remodelling genes (ATRX, H3F3A, DOT1L) in 5/14 samples (36%). In addition, two previously reported gene fusions (CLTC-VMP1 and FARP1-STK24) were identified in these tumours. In adamantinoma tumours, KMT2D, a histone methyltransferase, was recurrently mutated in 2/8 adamantinomas (25%). In addition, a cancer-predisposing germline fusion (KANSL1-ARL17A) was identified in 4/6 adamantinoma (66.7%) and in 3/4 OFD-like adamantinoma (75%) tumours. This thesis is a practical example demonstrating how rare diseases and cancers can be investigated using the same high-throughput techniques. Moreover, the three bone tumour studies represent the first comprehensive WES and RNA-Seq analyses conducted on these tumours, revealing novel molecular insights that can be translated into clinical practices to enhance the diagnosis, prognosis and the outcomes of patients with these diseases.

Degree

thesis:*
Name dc:type.qualificationname
d_ph
Level dc:type.qualificationlevel
d_ph
Grantor dc:publisher.institution
University of Birmingham
Year dc:date.issued
2019

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ali, Naser M.

Rights

Language dc:language.dcterms_iso639_2
eng

Chain of custody

source
Harvested from
University of Birmingham
Base URL
etheses.bham.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Ali, Naser M.. Genetic studies into rare diseases and cancer using next generation sequencing technologies. d_ph thesis, University of Birmingham, 2019.